The industry is currently navigating a pivot from legacy plasticized PVC to advanced polyolefin-based films. While this move toward non-DEHP materials satisfies stringent EU Medical Device Regulation (MDR) standards, it imposes a 15-20% increase in raw material costs. Manufacturers are absorbing these expenses to maintain access to critical Western healthcare networks, where clinical safety has become the primary procurement driver.
Operational logic is also shifting within hospital systems. The adoption of ready-to-administer multi-chamber bags has successfully reduced medication errors by 30%, prompting a move away from manual pharmacy compounding. To capitalize on this, major players like Baxter, B. Braun, and Fresenius Kabi are moving toward vertical integration, securing film extrusion capabilities to insulate themselves against petrochemical resin volatility.




Comments (0)
No comments yet. Be the first!